Access to Breast Cancer Diagnosis Act of 2020

Senate Bill 3216 - Access to Breast Cancer Diagnosis Act of 2020: Overview, Status, and Impact

Hozzl · 2022-02-08T23:22:54Z

Explore the details of Senate Bill 3216 Access to Breast Cancer Diagnosis Act of 2020 currently in Congress. Get insights into its purpose, current status, sponsors, and potential impact on Health. Stay informed on legislative developments.

2/8/2022, 11:22 PM

Congressional Summary of S 3216

Access to Breast Cancer Diagnosis Act of 2020

This bill prohibits private health insurance plans from imposing higher cost-sharing requirements on breast cancer diagnostic examinations than initial breast cancer screening examinations. Diagnostic examinations are generally required after an initial screening detects an abnormality and typically require additional mammogram images (e.g., x-rays).

Read the Full Bill

Formatted Text PDF Formatted XML

Current Status of Bill S 3216

Bill S 3216 is currently in the status of Bill Introduced since January 16, 2020. Bill S 3216 was introduced during Congress 116 and was introduced to the Senate on January 16, 2020. Bill S 3216's most recent activity was Read twice and referred to the Committee on Health, Education, Labor, and Pensions. as of January 16, 2020

Bipartisan Support of Bill S 3216

Total Number of Sponsors

Democrat Sponsors

Republican Sponsors

Unaffiliated Sponsors

Total Number of Cosponsors

Democrat Cosponsors

Republican Cosponsors

Unaffiliated Cosponsors

Policy Area and Potential Impact of Bill S 3216

Primary Policy Focus

Health

Potential Impact Areas

- Cancer

- Health care costs and insurance

- Health care coverage and access

- Health care quality

- Health promotion and preventive care

- Medical tests and diagnostic methods

- Women's health

Alternate Title(s) of Bill S 3216

Access to Breast Cancer Diagnosis Act of 2020

A bill to amend title XXVII of the Public Health Service Act to prohibit group health plans and health insurance issuers offering group or individual health insurance coverage from imposing cost-sharing requirements or treatment limitations with respect to diagnostic examinations for breast cancer that are less favorable than such requirements with respect to screening examinations for breast cancer.